234 related articles for article (PubMed ID: 30366412)
41. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
[TBL] [Abstract][Full Text] [Related]
42. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
43. (2
Idle JR; Seipel K; Bacher U; Pabst T; Beyoğlu D
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33019704
[TBL] [Abstract][Full Text] [Related]
44. Review of metabolic pathways activated in cancer cells as determined through isotopic labeling and network analysis.
Dong W; Keibler MA; Stephanopoulos G
Metab Eng; 2017 Sep; 43(Pt B):113-124. PubMed ID: 28192215
[TBL] [Abstract][Full Text] [Related]
45. Cancers converge at 2-HG.
Maxmen A
J Exp Med; 2010 Feb; 207(2):265. PubMed ID: 20142426
[No Abstract] [Full Text] [Related]
46. Profiling the Effect of Targeting Wild Isocitrate Dehydrogenase 1 (IDH1) on the Cellular Metabolome of Leukemic Cells.
Shait Mohammed MR; Alzahrani F; Hosawi S; Choudhry H; Khan MI
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743098
[TBL] [Abstract][Full Text] [Related]
47. 2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies.
Raimondi V; Ciotti G; Gottardi M; Ciccarese F
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740380
[TBL] [Abstract][Full Text] [Related]
48. An optimized method for measuring fatty acids and cholesterol in stable isotope-labeled cells.
Argus JP; Yu AK; Wang ES; Williams KJ; Bensinger SJ
J Lipid Res; 2017 Feb; 58(2):460-468. PubMed ID: 27974366
[TBL] [Abstract][Full Text] [Related]
49. Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity.
O'Brien C; Ling T; Berman JM; Culp-Hill R; Reisz JA; Rondeau V; Jahangiri S; St-Germain J; Macwan V; Astori A; Zeng A; Hong JY; Li M; Yang M; Jana S; Gamboni F; Tsao E; Liu W; Dick JE; Lin H; Melnick A; Tikhonova A; Arruda A; Minden MD; Raught B; D'Alessandro A; Jones CL
Haematologica; 2023 Sep; 108(9):2343-2357. PubMed ID: 37021547
[TBL] [Abstract][Full Text] [Related]
50. Fatty acid labeling from glutamine in hypoxia can be explained by isotope exchange without net reductive isocitrate dehydrogenase (IDH) flux.
Fan J; Kamphorst JJ; Rabinowitz JD; Shlomi T
J Biol Chem; 2013 Oct; 288(43):31363-9. PubMed ID: 24030823
[TBL] [Abstract][Full Text] [Related]
51. The metabolic reprogramming in acute myeloid leukemia patients depends on their genotype and is a prognostic marker.
Lo Presti C; Fauvelle F; Jacob MC; Mondet J; Mossuz P
Blood Adv; 2021 Jan; 5(1):156-166. PubMed ID: 33570627
[TBL] [Abstract][Full Text] [Related]
52. Berberine targets the electron transport chain complex I and reveals the landscape of OXPHOS dependency in acute myeloid leukemia with IDH1 mutation.
Huang Z; Shen Y; Liu W; Yang Y; Guo L; Yan Q; Wei C; Guo Q; Fan X; Ma W
Chin J Nat Med; 2023 Feb; 21(2):136-145. PubMed ID: 36871981
[TBL] [Abstract][Full Text] [Related]
53. High Expression of ACOT2 Predicts Worse Overall Survival and Abnormal Lipid Metabolism: A Potential Target for Acute Myeloid Leukemia.
Yin X; Lyu C; Li Z; Wang Q; Ding Y; Wang Y; Qiu Y; Cui S; Guo D; Xu R
J Healthc Eng; 2022; 2022():2669114. PubMed ID: 36193167
[TBL] [Abstract][Full Text] [Related]
54. Elevated plasma 2-hydroxyglutarate in acute myeloid leukaemia: association with the IDH1 SNP rs11554137 and severe renal impairment.
Wiseman DH; Small HF; Wilks DP; Waddell ID; Dennis MW; Ogilvie DJ; Somervaille TC
Br J Haematol; 2014 Jul; 166(1):145-8. PubMed ID: 24606602
[No Abstract] [Full Text] [Related]
55. Targeting IDH: the next big thing in AML.
Levis M
Blood; 2013 Oct; 122(16):2770-1. PubMed ID: 24136078
[No Abstract] [Full Text] [Related]
56. SMS121, a new inhibitor of CD36, impairs fatty acid uptake and viability of acute myeloid leukemia.
Åbacka H; Masoni S; Poli G; Huang P; Gusso F; Granchi C; Minutolo F; Tuccinardi T; Hagström-Andersson AK; Lindkvist-Petersson K
Sci Rep; 2024 Apr; 14(1):9104. PubMed ID: 38643249
[TBL] [Abstract][Full Text] [Related]
57.
Wiehle L; Raddatz G; Pusch S; Gutekunst J; von Deimling A; Rodríguez-Paredes M; Lyko F
Cell Stress; 2017 Sep; 1(1):55-67. PubMed ID: 31225434
[TBL] [Abstract][Full Text] [Related]
58. Metabolic Plasticity of Acute Myeloid Leukemia.
Kreitz J; Schönfeld C; Seibert M; Stolp V; Alshamleh I; Oellerich T; Steffen B; Schwalbe H; Schnütgen F; Kurrle N; Serve H
Cells; 2019 Jul; 8(8):. PubMed ID: 31370337
[TBL] [Abstract][Full Text] [Related]
59. Metabolomics in acute myeloid leukemia.
Wojcicki AV; Kasowski MM; Sakamoto KM; Lacayo N
Mol Genet Metab; 2020 Aug; 130(4):230-238. PubMed ID: 32457018
[TBL] [Abstract][Full Text] [Related]
60. Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia.
Chapuis N; Poulain L; Birsen R; Tamburini J; Bouscary D
Front Oncol; 2019; 9():405. PubMed ID: 31192118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
